Waters Corporation (WAT)
Automate Your Wheel Strategy on WAT
With Tiblio's Option Bot, you can configure your own wheel strategy including WAT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol WAT
- Rev/Share 51.1813
- Book/Share 36.2902
- PB 9.6064
- Debt/Equity 0.7123
- CurrentRatio 1.7538
- ROIC 0.1767
- MktCap 20751302201.0
- FreeCF/Share 10.4067
- PFCF 33.5047
- PE 31.3703
- Debt/Assets 0.3261
- DivYield 0
- ROE 0.3502
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | WAT | Rothschild & Co Redburn | -- | Buy | -- | $390 | Oct. 8, 2025 |
| Upgrade | WAT | KeyBanc Capital Markets | Sector Weight | Overweight | -- | $460 | March 31, 2025 |
| Upgrade | WAT | Robert W. Baird | Neutral | Outperform | $396 | $407 | March 26, 2025 |
| Upgrade | WAT | Scotiabank | Sector Perform | Sector Outperform | -- | $450 | Feb. 13, 2025 |
| Upgrade | WAT | Barclays | Underweight | Equal Weight | $360 | $415 | Feb. 10, 2025 |
| Upgrade | WAT | Bernstein | Market Perform | Outperform | -- | $430 | Jan. 10, 2025 |
| Initiation | WAT | Scotiabank | -- | Sector Perform | -- | -- | Dec. 23, 2024 |
| Upgrade | WAT | Jefferies | Hold | Buy | $355 | $415 | Oct. 8, 2024 |
| Initiation | WAT | Wells Fargo | -- | Overweight | -- | $380 | Aug. 28, 2024 |
News
Waters Corporation to Present at the Leerink Partners Global Healthcare Conference
Published: March 07, 2025 by: PRNewsWire
Sentiment: Neutral
MILFORD, Mass. , March 7, 2025 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced that Udit Batra Ph.D.
Read More
Waters Corporation: Instrument Replacement Cycle Momentum, But Valuation Is A Concern
Published: February 21, 2025 by: Seeking Alpha
Sentiment: Negative
Waters Corp reported better-than-expected Q4'24 and FY'24 results, driven by strong performance in academia, government, and pharma segments, despite FX headwinds impacting gross margins. The company anticipates continued growth in 2025, with projected revenue growth between 4.5% and 7%, supported by emerging markets like India and high-growth areas like GLP-1 and PFAS testing. Risks include elevated valuations and limited opportunities for cash deployment, making buybacks less attractive; current valuation appears challenging compared to historical averages and peers.
Read More
WAT Earnings & Sales Surpass Estimates in Q4, Shares Rise
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Neutral
WAT's fourth-quarter 2024 results reflect strong pharma growth and robust gains across all regions. However, forex headwinds hurt.
Read More
Waters Corporation (WAT) Q4 2024 Earnings Call Transcript
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Waters Corporation (NYSE:WAT ) Q4 2024 Earnings Conference Call February 12, 2025 8:00 AM ET Company Participants Caspar Tudor - Head of Investor Relations Udit Batra - President & Chief Executive Officer Amol Chaubal - Senior Vice President & Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies Vijay Kumar - Evercore ISI Puneet Souda - Leerink Eve Burstein - Bernstein Brandon Couillard - Wells Fargo Dan Arias - Stifel Dan Brennan - TD Cowen Catherine Schulte - Baird Operator Good morning. Welcome to the Waters Corporation Fourth Quarter 2024 Financial Results Conference Call.
Read More
Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2024 Financial Results
Published: February 12, 2025 by: PRNewsWire
Sentiment: Neutral
Highlights Fourth Quarter 2024 Sales of $873 million exceeded high-end of guidance range, grew 6% as reported and 8% in constant currency Instruments grew 8% and recurring revenue grew 9% in constant currency, as growth accelerated across all three reported regions Pharma grew 10% in constant currency, reflecting stronger-than-expected year-end spending dynamics and broad-based growth across the Americas, Europe, and Asia GAAP EPS of $3.88; non-GAAP EPS of $4.10 grew 13% as strong operational performance and better-than-expected sales volume offset foreign exchange headwinds Full-Year 2024 Sales exceeded guidance at $2,958 million, flat as reported and in organic constant currency GAAP …
Read More
About Waters Corporation (WAT)
- IPO Date 1995-11-17
- Website https://www.waters.com
- Industry Medical - Diagnostics & Research
- CEO Udit Batra
- Employees 7600